Science and Research

FDA Approves New Combination Therapy for People with Advanced EGFR+ NSCLC

2024-09-20T10:29:57-05:00September 20th, 2024|Hot Topics, News, Science and Research|

On September 19, 2024, the U.S. Food and Drug Administration (FDA) issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). The FDA approved this [...]

FDA Approves New Administration Method for Tecentriq (atezolizumab)

2024-09-16T16:06:41-05:00September 16th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that [...]

Go to Top